Основная статистика
| LEI | 549300YW6TUOX8BE5103 |
| CIK | 1367644 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Emergent BioSolutions Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| September 5, 2025 |
Exhibit 99.1 Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use GAITHERSBURG, Md., September 2, 2025 (GLOBE NEWSWIRE) - Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Dev |
|
| September 5, 2025 |
cyfendusmod AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE P00020 See Block 16C 6. ISSUED BY CODE AS PR-BARDA AS PR-BARDA 200 Independence Ave., s.w. Room 640-G Washington DC 20201 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. MERGENT PRODUCT DEVELOPMENT GAITHE 00 PROFESS |
|
| August 7, 2025 |
EX-4.5 Exhibit 4.5 EMERGENT BIOSOLUTIONS INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) Section 6.09 310(b) Section 6.08 Section 6.10 310(c) Inapplicable 311(a) Section 6.13 311(b) Section 6.13 311(c) Inapplicable 312(a) Section 4.01 Section 4.04 312(b) Section 4.04(c) 312(c) Sectio |
|
| August 7, 2025 |
Modification No. 19, effective April 4, 2025, to the BARDA AV av7909mod19redacted AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE P00019 See Block 16C 6. ISSUED BY CODE AS PR-BARDA AS PR-BARDA 200 Independence Ave., s.w. Room 640-G Washington DC 20201 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. MERGENT PRODUCT DEVELOPMENT GAITHE E |
|
| August 7, 2025 |
Calculation of Filing Fee Tables S-3 Emergent BioSolutions Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward |
|
| August 7, 2025 |
As filed with the Securities and Exchange Commission on August 7, 2025 S-3 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS |
|
| August 7, 2025 |
Form of Subordinated Indenture. EX-4.6 Exhibit 4.6 EMERGENT BIOSOLUTIONS INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 Section 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 |
|
| August 6, 2025 |
ebs2025-06x30q2deck 1 August 6, 2025 2025 Second Quarter Financial Results Our Mission: Protect and Save Lives 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 6, 2025 |
EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS •Second Quarter 2025 Total Revenues of $140. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| June 24, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| June 24, 2025 |
Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT Exhibit 99.1 Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply GAITHERSBURG, Md., June 23, 2025(GLOBE NEWSWIRE) - Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for Strategic Preparedne |
|
| May 23, 2025 |
UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND EX-99.1 UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND IN RE EMERGENT BIOSOLUTIONS INC., STOCKHOLDER DERIVATIVE LITIGATION Master Case No.: 8:21-cv-01595-DLB (Consolidated with No. 8:21-cv-02079-DLB) This Documents Relates To: ALL ACTIONS. STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation and Agreement of Settlement (the “Stipulation”) is made and entered into by and among the following |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 23, 2025 |
UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND EX-99.2 UNITED STATES DISTRICT COURT DISTRICT OF MARYLAND IN RE EMERGENT BIOSOLUTIONS INC., STOCKHOLDER DERIVATIVE LITIGATION Master Case No.: 8:21-cv-01595-DLB (Consolidated with No. 8:21-cv-02079-DLB) This Documents Relates To: ALL ACTIONS NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF DERIVATIVE ACTIONS EXHIBIT C TO: ALL PERSONS AND ENTITIES WHO OWNED EMERGENT BIOSOLUTIONS INC. COMMON STOCK AS O |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTION |
|
| May 7, 2025 |
1 May 7, 2025 Q1 2025 Financial Results 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| May 7, 2025 |
EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS •First Quarter 2025 Total Revenues of $222. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| March 31, 2025 |
Emergent BioSolutions Announces Stock Repurchase Program Emergent BioSolutions Announces Stock Repurchase Program GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company’s common stock on or before March 27, 2026. “As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our |
|
| March 31, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| March 24, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-283150 PROSPECTUS Emergent BioSolutions Inc. Up to 3,613,338 shares of Common Stock 2,500,000 Warrants to Purchase up to 2,500,000 Shares of Common Stock This prospectus relates to the offer and sale from time to time, by the selling securityholders identified in this prospectus, of (i) up to 3,613,338 shares of the common sto |
|
| March 24, 2025 |
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International GAITHERSBURG, Md. |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| March 21, 2025 |
2024 ANNUAL REPORT PREPAREDNESS TODAY, SAFER TOMORROW. 300 Professional Drive, Gaithersburg, Maryland 20879 USA emergentbiosolutions.com Dear fellow shareholders, When I joined Emergent in February 2024, we embarked on a multi-year plan to stabilize, turnaround, and ultimately transform our business. I am proud to say our stabilization phase was completed this past fall, ahead of schedule, thanks |
|
| March 21, 2025 |
emergentbiosolutionsincn Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant☒ Filed by a party other than the Registrant☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| March 10, 2025 |
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International GAITHERSBURG, Md. |
|
| March 4, 2025 |
List of Subsidiaries (as of December 31, 2024) Name of Subsidiary Jurisdiction of Incorporation or Organization Domestic 400 Professional LLC Delaware Cangene bioPharma LLC Maryland Emergent Commercial Operations Frederick Inc. |
|
| March 4, 2025 |
Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. CREDIT AGREEMENT by and among WELLS FARGO BANK, NATIONAL ASSOCIATION, as Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Sole Lead Arranger, WELLS FARGO BANK, NATIO |
|
| March 4, 2025 |
Form 10-K for the fiscal year ended December 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC |
|
| March 4, 2025 |
Authorized Global Policy Insider Trading Policy 1 Global Policy : Insider Trading Policy Insider Trading Policy Purpose & Scope The purpose of this Policy is to: • Provide general guidelines to all members of the Board of Directors (“Board Members”), officers, employees and designated consultants of Emergent BioSolutions Inc. |
|
| March 4, 2025 |
Description of the Company's Securities exhibit41-descriptionoft Exhibit 4.1 EMERGENT BIOSOLUTIONS INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHNAGE ACT OF 1934 Emergent BioSolutions Inc. (“we”, “our” and “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.001 par value per share. The following summary of common s |
|
| March 4, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Emergent BioSolutions Inc. |
|
| March 4, 2025 |
As filed with the Securities and Exchange Commission on March 4, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. |
|
| March 4, 2025 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-283150 PROSPECTUS SUPPLEMENT NO. 1 (to prospectus dated December 4, 2024) Emergent BioSolutions Inc. Up to 3,613,338 shares of Common Stock 2,500,000 Warrants to Purchase up to 2,500,000 Shares of Common Stock This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 4, 2024 |
|
| March 4, 2025 |
Exhibit 10.76 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. LICENSE AGREEMENT between LIGHTLAKE THERAPEUTICS INC. and ADAPT PHARMA OPERATIONS LIMITED Dated as of December 15, 2014 1 LICENSE AGREEMENT This License Agree |
|
| March 4, 2025 |
As filed with the Securities and Exchange Commission on March 4, 2025 As filed with the Securities and Exchange Commission on March 4, 2025 Registration No. |
|
| March 3, 2025 |
1 March 3, 2025 Q4 2024 & Full Year Financial Results 2 Safe Harbor Statement/Trademarks 2 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| March 3, 2025 |
EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS •Fourth Quarter 2024 Total Revenues of $194. |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction of incorporation) (Commis |
|
| January 15, 2025 |
January 15, 2025 43rd Annual J.P. Morgan Healthcare Conference Joe Papa President & CEO Exhibit 99.1 This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business str |
|
| January 14, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| January 14, 2025 |
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals •Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose emergency treatments to patients, customers and communities in need •Focus remains on increasing access, raising awareness and ensuring strong supply to meet the ongoing demand of naloxone nasal spray GAITHERSBURG, Md. |
|
| January 8, 2025 |
Modification No. 3, effective December 13, 2024, to the BioThrax IDIQ Contract biothraxmod SEE SCHEDULE AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect. |
|
| January 8, 2025 |
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) GAITHERSBURG, Md., Jan. 8, 2024 (GLOBE NEWSWIRE) – Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Departme |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| January 8, 2025 |
Modification No. 18, effective December 12, 2024, to the BARDA AV909 Contract cyfendusmod as an initial procurement to the Strategic National Stockpile {SNS). Emergent will be responsible for shipping and transport of filled and finished AV7909 product to the SNS and the costs associated with the delivery. Under CLIN 0006 Emergent shall manufacture, fill, and deliver [**] doses procured from [**] through [**], as an additional procurement to the SNS. Emergent will be respon |
|
| January 8, 2025 |
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) GAITHERSBURG, Md. |
|
| December 4, 2024 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-283150 PROSPECTUS Emergent BioSolutions Inc. Up to 3,613,338 shares of Common Stock 2,500,000 Warrants to Purchase up to 2,500,000 Shares of Common Stock This prospectus relates to the offer and sale from time to time, by the selling securityholders identified in this prospectus, of (i) up to 3,613,338 shares of the common sto |
|
| December 2, 2024 |
December 2, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Emergent BioSolutions Inc. Registration Statement on Form S-1 File No. 333-283150 Filed November 12, 2024 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Emergent BioSolutions Inc. hereby respectfully requests |
|
| December 2, 2024 |
As filed with the Securities and Exchange Commission on December 2, 2024 S-1/A Table of Contents As filed with the Securities and Exchange Commission on December 2, 2024 Registration No. |
|
| November 13, 2024 |
SC 13G 1 p24-3235sc13g.htm EMERGENT BIOSOLUTIONS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Emergent BioSolutions Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29089Q105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) |
|
| November 12, 2024 |
Exhibit 21 List of Subsidiaries (as of November 12, 2024) Name of Subsidiary Jurisdiction of Incorporation or Organization Domestic Domestic 400 Professional LLC Delaware Cangene bioPharma LLC Maryland Emergent Commercial Operations Frederick Inc. |
|
| November 12, 2024 |
As filed with the Securities and Exchange Commission on November 12, 2024 Table of Contents As filed with the Securities and Exchange Commission on November 12, 2024 Registration No. |
|
| November 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Emergent BioSolutions Inc. |
|
| November 8, 2024 |
SC 13G/A 1 ebsa1110724.htm CHARLES SCHWAB INVESTMENT MANAGEMENT INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Emergent BioSolutions Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29089Q105 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement |
|
| November 7, 2024 |
Execution Version STOCK AND ASSET PURCHASE AGREEMENT by and between EMERGENT BIOSOLUTIONS CANADA INC. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLU |
|
| November 6, 2024 |
EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS •Third Quarter 2024 Total Revenues of $293. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| November 6, 2024 |
Q3 2024 Financial Results Update November 6, 2024 Proprietary & Confidential PROPRIETARY AND CONFIDENTIAL Q3 2024 Update Introduction This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| October 2, 2024 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is (i) not material and (ii) the type of information that the registrant treats as private or confidential. CREDIT AGREEMENT by and among WELLS FARGO BANK, NATIONAL ASSOCIATION, as Agent, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Sole Lead Arranger, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Sole Book Runne |
|
| October 2, 2024 |
Exhibit 99.1 Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility GAITHERSBURG, Md., Oct 2, 2024 – Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an asset-based revolving loan facility (ABL) with the lenders party thereto and Wells Fargo Bank, National Association, as administrativ |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction of incorporation) (Comm |
|
| September 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number |
|
| September 3, 2024 |
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile Exhibit 99.1 Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile • New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the company GAITHERSBURG, Md., September 3, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the closing of a new credit |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction of incorporation) (Commiss |
|
| September 3, 2024 |
Certain identified information has been excluded from this exhibit because it is (i) not material and (ii) the type of information that the registrant treats as private or confidential. |
|
| September 3, 2024 |
Exhibit 4.2 FIRST SUPPLEMENTAL INDENTURE First Supplemental Indenture (this “First Supplemental Indenture”), dated as of August 30, 2024, among each of the entities listed in the Schedule to this Supplemental Indenture as guaranteeing subsidiaries (each a “Guaranteeing Subsidiary” and together, the “Guaranteeing Subsidiaries”), each being a subsidiary of Emergent BioSolutions Inc., a Delaware corp |
|
| September 3, 2024 |
Exhibit 10.3 Execution Version FORM OF SUBSCRIPTION AGREEMENT This subscription agreement (this “Agreement”) dated as of August 30, 2024, is made by and between Emergent BioSolutions Inc., a Delaware limited liability company (the “Company”), and OHA CA Customized Credit Fund, L.P. – OHA Senior Private Lending Fund (CA 3), OHA CA Customized Credit Fund, L.P. – OHA Senior Private Lending Fund (CA 5 |
|
| September 3, 2024 |
Exhibit 10.2 Execution Version WARRANT AGREEMENT BETWEEN EMERGENT BIOSOLUTIONS INC. AND BROADRIDGE CORPORATE ISSUER SOLUTIONS LLC, AS WARRANT AGENT August 30, 2024 TABLE OF CONTENTS Page SECTION 1. Appointment of Warrant Agent 1 SECTION 2. Issuances; Exercise Price 1 SECTION 3. Form of Warrants 2 SECTION 4. Execution of Global Warrant Certificates 2 SECTION 5. Registration and Countersignature 3 S |
|
| August 30, 2024 |
Emergent BioSolutions’ ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U. |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| August 20, 2024 |
Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals GAITHERSBURG, Md. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| August 6, 2024 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Emergent BioSolutions Inc. |
|
| August 6, 2024 |
ebs2024-06x30deckfinal Q2 2024 Financial Results Update August 6, 2024 PROPRIETARY AND CONFIDENTIAL Q2 2024 Update Introduction This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 6, 2024 |
EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS •Second Quarter 2024 Total Revenues of $254. |
|
| August 6, 2024 |
As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Reference No 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EMERGENT BIOSOLUTIONS INC. |
|
| July 31, 2024 |
Emergent BioSolutions Completes Sale of RSDL Emergent BioSolutions Completes Sale of RSDL® (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million GAITHERSBURG, Md. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| July 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| July 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| July 2, 2024 |
Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U. |
|
| July 2, 2024 |
Modification No. 12, effective June 28, 2024, to the ACAM2000 Contract a75a50119c00071p00012xs AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE P00012 See Block 16C 6. ISSUED BY CODE ASPR/SNS ASPR/SNS ASPR/SNS 2945 FLOWERS ROAD ATLANTA, GA 30341 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. ttn: STEVE RAMBO MERGENT PRODUCT DEVELOPMENT GAITHE 1 |
|
| July 2, 2024 |
Modification No. 17, effective June 26, 2024, to the BARDA AV7909 Contract 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing Items 8 and 15, and |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| June 20, 2024 |
Emergent BioSolutions Announces Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals for $30 Million GAITHERSBURG, Md. |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 29, 2024 |
Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan EMERGENT BIOSOLUTIONS INC. AMENDED AND RESTATED STOCK INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated Stock Incentive Plan (the “Plan”) of Emergent BioSolutions Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contri |
|
| May 29, 2024 |
ebsvasm2024asof52224fin PROPRIETARY AND CONFIDENTIAL Emergent BioSolutions M A Y 2 3 , 2 0 2 4 2 0 2 4 A N N U A L M E E T I N G O F S T O C K H O L D E R S PROPRIETARY AND CONFIDENTIAL • Call to Order; Rules and Procedure • Introductions • Procedural Matters; Declaration of Quorum • Presentation of the proposals to be considered and voted on by the stockholders as set forth in the proxy statement |
|
| May 2, 2024 |
Modification No. 1, effective February 13, 2024 to the BioThrax IDIQ Contract AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 11. CON1RA� ID CODE I PAGEOF PAGES 1 1 3 2. AMENDMENT/MODIFICATION NO. 3.EFFECI1\ |
|
| May 2, 2024 |
Modification No. 2, effective March 21, 2024 to the BioThrax IDIQ Contract AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 11. CON1RACTID CODE I PAGE OF PAGES 1 I s 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DAlE 4. REQUISITION/PURCHASE REQ. NO. 15. PROJECTNO.(Ifapplicable) P00002 21-Mar-2024 SEE SCHEDULE 6.ISSUEDBY CODE V1,911SR 7. ADMINIS1ERED BY (lfother than item6) CODE Im11sR USA CONTRACTING CMD-APG. - W311SR USA CONTRACTING CMD-APG. - W311SR 110 THOMASJOHNSON DR |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTION |
|
| May 2, 2024 |
Brian Mazen/Contracting Officer 520-671-3728 [email protected] 1/9/2024 [* *] [* *] Certain identified information has been excluded from this exhibit because it is (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omission. [* *] [* *] W911SR24D0001 Page 6 of26 ITEM NO SUPPLIES/SERVICES MAX QUANTITY 1001 UN |
|
| May 2, 2024 |
emergent-seventhamendmen EXECUTION VERSION CONSENT, WAIVER AND SEVENTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT CONSENT, WAIVER AND SEVENTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of April 29, 2024, among EMERGENT BIOSOLUTIONS INC. |
|
| May 2, 2024 |
Delivery Order 1, effective January 22, 2024 to the BioThrax IDIQ Contract SEE ADDENDUM (No Collect Calls)b. TELEPHONE NUMBER 8. OFFER DUE DATE/LOCAL TIME 5. SOLICITATION NUMBER 6. SOLICITATION ISSUE DATE AUTHORIZED FOR LOCAL REPRODUCTION PREVIOUS EDITION IS NOT USABLE STANDARD FORM 1449 (REV. 2/2012) Prescribed by GSA – FAR (48 CFR) 53.212 (TYPE OR PRINT) (SIGNATURE OF CONTRACTING OFFICER) ADDENDA ARE 26. TOTAL AWARD AMOUNT (For Gov t. Use Only ) 23. CODE 10. THIS ACQUI |
|
| May 1, 2024 |
EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS •First Quarter 2024 Total Revenues of $300. |
|
| May 1, 2024 |
Modification No. 11, effective April 29, 2024, to the ACAM2000 Contract 4/29/2024 [**] Certain identified information has been excluded from this exhibit because it is (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| May 1, 2024 |
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position •Proactive changes aim to ensure long-term sustainability and growth, optimize operations, streamline processes, and allocate resources more efficiently •Reorganization will align with evolving business goals, strategic priorities and new operational plan •Overall efforts expected to deliver annual cost savings of approximately $80 million GAITHERSBURG, Md. |
|
| May 1, 2024 |
Q1 2024 Financial Results Update May 1, 2024 1 PROPRIETARY AND CONFIDENTIAL 2 Q1 2024 Update Introduction This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| April 30, 2024 |
Emergent BioSolutions Announces Amendment to its Existing Credit Facility Emergent BioSolutions Announces Amendment to its Existing Credit Facility GAITHERSBURG, Md. |
|
| April 26, 2024 |
Form of Amendment to Letter Agreement, dated April 23, 2024 WEIL:\99660008\5\43717.0003 April [ ], 2024 NAME ADDRESS Via Email: [email protected] RE: Amendment to Key Employee Retention Program Dear [ ]: In recognition of your continuing key role at Emergent BioSolutions Inc. (the "Company"), you and the Company entered into a Key Employee Retention Program Agreement dated July [ ], 2023 (the “KERP Agreement”). The Company and you have determined to amend and s |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for |
|
| April 11, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ |
|
| March 8, 2024 |
Modification No. 7, effective October 6, 2022, to the ACAM2000 Contract modificationno7effective |
|
| March 8, 2024 |
Modification No. 15, effective October 6, 2023, to the BARDA AV7909 Contract modificationno15effectiv Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
|
| March 8, 2024 |
Modification No. 8, effective November 21, 2022, to the ACAM2000 Contract modificationno8effective |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC |
|
| March 8, 2024 |
ifth Amendment to Amended and Restated Credit Agreement, dated July 14, 2023 fifthamendmenttoamendeda EXECUTION VERSION 1751066454 FIFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT FIFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), dated as of July 14, 2023, among EMERGENT BIOSOLUTIONS INC. |
|
| March 8, 2024 |
Modification No. 16, effective November 21, 2023, to the BARDA AV7909 Contract modificationno16effectiv AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE P00016 See Block 16C 6. ISSUED BY CODE AS PR-BARDA AS PR-BARDA 200 Independence Ave., s.w. Room 640-G Washington DC 20201 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. MERGENT PRODUCT DEVELOPMENT GAIT |
|
| March 8, 2024 |
List of Subsidiaries (as of December 31, 2023) Name of Subsidiary Jurisdiction of Incorporation or Organization Domestic 400 Professional LLC Delaware Cangene bioPharma LLC Maryland Emergent Commercial Operations Frederick Inc. |
|
| March 8, 2024 |
Emergent BioSolutions Compensation Recovery Policy, effective October 26, 2023 emergentbiosolutionscomp ${vault:statusv} ${vault:governing sitec} ${vault:subtypev} ${vault:titlev} 1 Emergent BioSolutions Compensation Recovery Policy Purpose & Scope The purpose of this Compensation Recovery Policy (the “Policy”), is to: Comply with applicable law and any rules or regulations adopted by the Securities and Exchange Commission, including Section 10D-1 under the Securities Exchange Act of 1934, the rules promulgated by the Securities and Exchange Commission thereunder, and the listing standards of the New York Stock Exchange (collectively, the “Applicable Rules”). |
|
| March 6, 2024 |
emergent-forbearanceagre EXECUTION VERSION WEIL:\99600594\1\43717.0003 FORBEARANCE AGREEMENT AND SIXTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT This Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement, dated as of February 29, 2024 (this “Forbearance Agreement and Amendment”), is entered into by and among EMERGENT BIOSOLUTIONS INC., a Delaware corporation ( |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| March 6, 2024 |
ebs2023-12x31deckfinalmi Q4 2023 Financial Results Update March 6, 2024 1 PROPRIETARY AND CONFIDENTIAL 2 Q4 2023 Update Introduction This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| March 6, 2024 |
EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS •Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidance •Full Year 2023 Total Revenues of $1. |
|
| February 21, 2024 |
Executive Agreement, dated February 19, 2024 between Emergent BioSolutions Inc. and Joseph Papa EMERGENT BIOSOLUTIONS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”), dated as of February 19, 2024 is made and entered into by Emergent BioSolutions, Inc. (the “Company”) and Joseph Papa (the “Executive”). WHEREAS, the Company and the Executive desire to enter into this Agreement to set forth the terms and conditions of the Executive’s employment as th |
|
| February 21, 2024 |
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO FOR IMMEDIATE RELEASE Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO •Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., February 21, 2024 – Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| February 13, 2024 |
EBS / Emergent BioSolutions Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0834-emergentbiosolutionsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Emergent BioSolutions Inc Title of Class of Securities: Common Stock CUSIP Number: 29089Q105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 9, 2024 |
SC 13G 1 ebs20824.htm CHARLES SCHWAB INVESTMENT MANAGEMENT INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Emergent BioSolutions Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29089Q105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate b |
|
| January 18, 2024 |
EBS / Emergent BioSolutions Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) EMERGENT BIOSOLUTIONS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29089Q105 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate t |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| January 11, 2024 |
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense GAITHERSBURG, Md., Jan. 11, 2024 - Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThra |
|
| January 9, 2024 |
ebsjpmpresentationslides 42nd Annual J.P. Morgan Healthcare Conference January 2024 Haywood Miller Interim CEO Rich Lindahl CFO This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or our business |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| January 9, 2024 |
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 GAITHERSBURG, Md., January 9, 2024 – Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Chief Financial Offi |
|
| December 13, 2023 |
As filed with the Securities and Exchange Commission on December 12, 2023 As filed with the Securities and Exchange Commission on December 12, 2023 Registration No. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLU |
|
| December 11, 2023 |
Emergent BioSolutions Inc. Inducement Plan EMERGENT BIOSOLUTIONS INC. INDUCEMENT PLAN 1. Purpose The purpose of this Inducement Plan (the “Plan”) of Emergent BioSolutions Inc., a Delaware corporation (the “Company”), is to enable the Company to provide a material inducement to prospective employees who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performan |
|
| December 11, 2023 |
Form of Letter Agreement, dated July 26, 2023 July 25, 2023 [Name] [Address] Via Email: RE: Key Employee Retention Program Dear [Name] In recognition of your continuing key role at Emergent BioSolutions Inc. |
|
| December 11, 2023 |
As filed with the Securities and Exchange Commission on December 11, 2023 S-8 As filed with the Securities and Exchange Commission on December 11, 2023 Registration No. |
|
| December 11, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Emergent BioSolutions Inc. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGEN |
|
| November 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| November 28, 2023 |
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted) GAITHERSBURG, Md. |
|
| November 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| November 24, 2023 |
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing GAITHERSBURG, Md. |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-33137 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report |
|
| November 8, 2023 |
ebs2023-09x30deckcopyfin Q3 2023 Financial Results Update November 8, 2023 PROPRIETARY AND CONFIDENTIALQ3 2023 Update Introduction This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| November 8, 2023 |
EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS •Third Quarter 2023 Total Revenues of $271M, above the prior guidance range •Third Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA(2) of $20M •Updates FY 2023 guidance GAITHERSBURG, Md. |
|
| October 10, 2023 |
EBS / Emergent Biosolutions Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Emergent BioSolutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 29089Q105 Date of Event Which Requires Filing of this Statement: September 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| October 5, 2023 |
A Statement on Emergent’s Camden Manufacturing Facility Regulatory Status GAITHERSBURG, Md. |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number |
|
| October 2, 2023 |
FOR IMMEDIATE RELEASE Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors GAITHERSBURG, Md. |
|
| October 2, 2023 |
Emergent BioSolutions Inc. Inducement Plan 1 EMERGENT BIOSOLUTIONS INC. INDUCEMENT PLAN 1. Purpose The purpose of this Inducement Plan (the “Plan”) of Emergent BioSolutions Inc., a Delaware corporation (the “Company”), is to enable the Company to provide a material inducement to prospective employees who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and perform |
|
| September 7, 2023 |
EBS / Emergent Biosolutions Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 EMERGENT BIOSOLUTIONS INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 29089Q105 (CUSIP Number) AUGUST 30, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to |
|
| August 30, 2023 |
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency •Emergent has officially shipped its over the counter, original prescription strength NARCAN® Naloxone HCl Nasal Spray 4 mg to leading mass, drug/pharmacy and grocery stores, as well as online retailers •NARCAN® Nasal Spray will be the first, life-saving emergency medicine for opioid overdose available on shelves beginning this September with a Manufacturer’s Suggested Retail Price of $44. |
|
| August 30, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| August 16, 2023 |
Emergent’s Statement Regarding the Passing of a Director of the Board Emergent’s Statement Regarding the Passing of a Director of the Board GAITHERSBURG, Md. |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS |
|
| August 9, 2023 |
, by and between Emergent BioSolutions Inc. and Haywood Miller. 99 High Street, 27th Floor | Boston, MA 02110 Berkeley Research Group, LLC | 877.696.0391 | www.thinkbrg.com PRIVILEGED AND CONFIDENTIAL July 7, 2023 Via Email Dr. Zsolt Harsanyi [**] Re: Emergent BioSolutions – Interim CEO Dear Dr. Harsanyi: This letter confirms that the Board of Directors (“Board”) of Emergent BioSolutions Inc. (collectively with its designated affiliates, the “Company”) has eng |
|
| August 9, 2023 |
Modification No. 13, effective March 30, 2023, to the BARDA AV7909 Contract AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE P00013 See Block 16C 6. ISSUED BY CODE AS PR-BARDA AS PR-BARDA 200 Independence Ave., s.w. Room 640-G Washington DC 20201 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. MERGENT PRODUCT DEVELOPMENT GAITHE 00 PROFESSIONAL DR# 10 |
|
| August 9, 2023 |
Modification No. 10, effective May 26, 2023, to the ACAM2000 Contract |
|
| August 9, 2023 |
Modification No. 9, effective May 24, 2023, to the ACAM2000 Contract |
|
| August 9, 2023 |
Modification No. 14, effective March 30, 2023, to the BARDA AV7909 Contract AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 2. AMENDMENT/MODIFICATION NO. 3. EFFECTIVE DATE P00014 See Block 16C 6. ISSUED BY CODE AS PR-BARDA AS PR-BARDA 200 Independence Ave., s.w. Room 640-G Washington DC 20201 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) MERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. MERGENT PRODUCT DEVELOPMENT GAITHE 00 PROFESSIONAL DR# 10 |
|
| August 8, 2023 |
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost savings over $100 million annually GAITHERSBURG, Md. |
|
| August 8, 2023 |
deck-2q23xfinalxtobefile Q2 2023 Financial Results Update August 8, 2023 PROPRIETARY AND CONFIDENTIAL 2Q2 2023 Update Introduction Matt Hartwig Senior Director, Media Relations This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| August 8, 2023 |
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2023 •Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M •Updates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues GAITHERSBURG, Md. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| July 31, 2023 |
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Matt Hartwig Senior Director, Media Relations [email protected] Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola GAITHERSBURG, Md., July 31, 2023 – Emergent Bi |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| July 27, 2023 |
formofletteragreement726 July 25, 2023 [Name] [Address] Via Email: RE: Key Employee Reten on Program Dear [Name] In recogni on of your con nuing key role at Emergent BioSolu ons Inc. |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| July 21, 2023 |
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Matt Hartwig Senior Director, Media Relations [email protected] Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use –Emergent has been del |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IR |
|
| June 27, 2023 |
a062723-emergentannounce Investor Contact Robert Burrows Vice President, Investor Relations burrowsr@ebsi. |
|
| June 5, 2023 |
EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Table Form S-8 (Form Type) Emergent BioSolutions Inc. |
|
| June 5, 2023 |
Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan EX-4.4 Exhibit 4.4 EMERGENT BIOSOLUTIONS INC. AMENDED AND RESTATED STOCK INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated Stock Incentive Plan (the “Plan”) of Emergent BioSolutions Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to ma |
|
| June 5, 2023 |
As filed with the Securities and Exchange Commission on June 5, 2023 S-8 As filed with the Securities and Exchange Commission on June 5, 2023 Registration No. |
|
| June 5, 2023 |
Emergent BioSolutions Inc. Amended Employee Stock Purchase Plan EX-4.5 Exhibit 4.5 EMERGENT BIOSOLUTIONS INC. AMENDED EMPLOYEE STOCK PURCHASE PLAN The purpose of this Amended Plan (the “Plan”) is to provide eligible employees of Emergent BioSolutions Inc. (the “Corporation”) and certain of its subsidiaries with opportunities to purchase shares of the Corporation’s common stock, $0.001 par value (the “Common Stock”). Three million (3,000,000) shares of Common S |
|
| May 31, 2023 |
ebsvasm2023-slidesxfinal Emergent BioSolutions Inc. 2023 Annual Meeting of Stockholders May 25, 2023 Agenda 22023 Virtual Annual Meeting of Stockholders INTRODUCTION 1. Call to Order; Rules and Procedure 2. Introductions 3. Procedural Matters; Declaration of Quorum 4. Presentation of the proposals to be considered and voted on by the stockholders as set forth in the proxy statement: • Proposal No. |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 30, 2023 |
emergent053023pracam-fin Emergent BioSolutions Announces the Execution of a Contract Option to Deliver ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) into the Strategic National Stockpile • Order is for approximately $120 million of smallpox vaccine for delivery in 2023 • Reaffirms ACAM2000® is a key component of the U. |
|
| May 18, 2023 |
Exhibit 10.1 EXECUTION VERSION Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain information (indicated by [***]) has been omitted from Exhibit 10.1 because (i) it is not material and (ii) the Registrant customarily and actually treats such information as private or confidential. FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT, WAIVER AND FIRST AMENDMENT TO AMENDED AND RESTATED |
|
| May 18, 2023 |
Emergent’s Statement Regarding its Amended Credit Agreement EX-99.1 Exhibit 99.1 Emergent’s Statement Regarding its Amended Credit Agreement GAITHERSBURG, Md., May 17, 2023 – Emergent (NYSE: EBS) completed an amendment and extension of maturity of its existing syndicated credit agreement on May 15, 2023. We believe this revised structure and extended maturity furthers our ability to execute on our strategy to stabilize and strengthen our core business and |
|
| May 18, 2023 |
Equity Distribution Agreement, dated May 17, 2023 Exhibit 10.2 EMERGENT BIOSOLUTIONS INC. Common Stock (par value $0.001 per share) Having an Aggregate Offering Price of up to Up to $150,000,000 Equity Distribution Agreement May 17, 2023 Evercore Group L.L.C. 55 East 52nd Street, 36th Floor New York, New York 10055 RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor New York, New York 10281 Ladies and Gentlemen: Emergent BioSolu |
|
| May 18, 2023 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(5) (Form Type) EMERGENT BIOSOLUTIONS INC. |
|
| May 18, 2023 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Number 333-258634 PROSPECTUS SUPPLEMENT (To prospectus dated August 9, 2021) $150,000,000 Common Stock We have entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Evercore Group L. |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2023 |
Emergent BioSolutions Inc. and Subsidiaries Unaudited Pro Forma Condensed Consolidated Financial Information On February 15, 2023, Emergent BioSolutions Inc. (“Emergent”), through its wholly owned subsidiaries Emergent International Inc. and Emergent Travel Health Inc. (collectively the “Company”) entered into a Purchase and Sale Agreement (the “Definitive Agreement”) with Bavarian Nordic (“Bavari |
|
| May 15, 2023 |
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic GAITHERSBURG, Md. |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| May 10, 2023 |
- 1 - Certain portions of this exhibit were omitted by means of marking such portions with asterisk because the identified confidential portions would be competitively harmful if publicly disclosed and they are the type of information that the registrant treats as private or confidential. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTION |
|
| May 9, 2023 |
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2023 •Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M •Updates FY 2023 guidance and provides initial Q2 2023 guidance GAITHERSBURG, Md. |
|
| May 9, 2023 |
ebs1q23calldeck-final Q1 2023 Financial Results Update May 9, 2023 PROPRIETARY AND CONFIDENTIAL 2Q1 2023 Investor Update Introduction Bob Burrows Vice President, Investor Relations This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (IRS |
|
| April 24, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14A-101) Schedule 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| April 17, 2023 |
emergent041723statement Emergent BioSolution’s Statement on the Status of its Credit Facility and the Sale of its Travel Health Business GAITHERSBURG, Md. |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| April 14, 2023 |
DEFA14A 1 d479088ddefa14a.htm DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: |
|
| April 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| March 29, 2023 |
narcanotcapprovalpressre U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment • NARCAN® Naloxone HCl Nasal Spray 4 mg is currently the first and only prescription strength naloxone nasal spray to receive over-the-counter status in the U.S., which is a critical step toward broadening access • |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) (I |
|
| March 23, 2023 |
Form of 2023-2025 Performance Based Stock Unit Award Agreement exccompmins2-9x23v1x202 - 1 - Certain portions of this exhibit were omitted by means of marking such portions with asterisk because the identified confidential portions would be competitively harmful if publicly disclosed and they are the type of information that the registrant treats as private or confidential. |
|
| March 1, 2023 |
purchaseandsaleagreement EXECUTION VERSION CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| March 1, 2023 |
ebsstockincentiveplan-ja 1 DC: 8281717-4 EMERGENT BIOSOLUTIONS INC. AMENDED AND RESTATED STOCK INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated Stock Incentive Plan (the “Plan”) of Emergent BioSolutions Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons |
|
| March 1, 2023 |
listofsubsidiariesasofde List of Subsidiaries (as of December 31, 2022) Name of Subsidiary Jurisdiction of Incorporation or Organization Domestic 400 Professional LLC Delaware Cangene bioPharma LLC Maryland Emergent Commercial Operations Frederick Inc. |
|
| March 1, 2023 |
Consent, Limited Waiver, and Third Amendment to the Amended and Restated Credit Agreement consentlimitedwaiverandt EXECUTION VERSION WEIL:\98983270\8\43717.0003 CONSENT, LIMITED WAIVER AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT CONSENT, LIMITED WAIVER AND THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Consent and Limited Waiver”), dated as of February 14, 2023, among EMERGENT BIOSOLUTIONS INC., a Delaware corporation (the “Borrower”), the Guarantors ( |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| February 27, 2023 |
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER 2022 •Reports Q4 2022 total revenues of $331M resulting in FY 2022 total revenues of $1,121M, in line with prior guidance •Reports Q4 2022 net loss of $88M and FY 2022 net loss of $224M •Reports Q4 2022 adjusted EBITDA of $34M and FY 2022 adjusted EBITDA of $26M, in line with prior guidance •Reports Q4 2022 adjusted gross margin of 48% and FY 2022 adjusted gross margin of 41% •For FY 2023, expects continued stability of revenues and further improvements in operations and normalizing of cost structure leading to guidance of total revenues of $1,150M, adjusted EBITDA of $100M, and adjusted gross margin of 43%, all at the midpoint GAITHERSBURG, Md. |
|
| February 27, 2023 |
EX-99.2 3 ebs4qfy22calldeck-final.htm EX-99.2 Q4FY 2022 Financial Results Update February 27, 2023 PROPRIETARY AND CONFIDENTIAL 2Q4FY 2022 Investor Update Introduction Bob Burrows Vice President, Investor Relations Officer EMERGE NT" This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statement |
|
| February 15, 2023 |
EX-99.1 2 privconfebsemeraldrelea.htm EX-99.1 Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million GAITHERSBURG, Md., February 15, 2023 – Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a total value of up to $380 million, including potential |
|
| February 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| February 9, 2023 |
EBS / Emergent Biosolutions Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0810-emergentbiosolutionsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Emergent BioSolutions Inc. Title of Class of Securities: Common Stock CUSIP Number: 29089Q105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo |
|
| January 9, 2023 |
Emergent BioSolutions Announces Organizational Changes as part of Sharpened Strategic Focus Announces Preliminary 2022 Financial Results GAITHERSBURG, Md. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| January 5, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| January 5, 2023 |
EX-99.1 2 emergentbiosolutionssign.htm EX-99.1 Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense GAITHERSBURG, Md., Jan. 5, 2023 (GLOBE NEWSWIRE) - Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a ma |
|
| December 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2022 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| December 6, 2022 |
narcanotcfilingacceptanc Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray December 6, 2022 Emergent’s supplemental new drug application is the first prescription-to-over-the-counter switch application in history to be granted Priority Review by the FDA. NARCAN® (naloxone HCI) Nasal S |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLU |
|
| November 8, 2022 |
ebs3q22calldeck-final 3Q 2022 Financial Results Update November 8, 2022 PROPRIETARY AND CONFIDENTIAL 23Q 2022 Investor Update Introduction Robert G. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| November 8, 2022 |
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2022 GAITHERSBURG, Md. |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number |
|
| September 26, 2022 |
Investor Contact Robert Burrows Vice President, Investor Relations [email protected] (240) 413-1917 Media Contact Matt Hartwig Senior Director, Media Relations [email protected] Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA? (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages GAITHERSBURG, Md., September 26, 2022 ? Emergent BioS |
|
| August 12, 2022 |
Emergent BioSolution?s Statement on the Status of its Camden Manufacturing Facility? GAITHERSBURG, Md. |
|
| August 12, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2022 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) ( |
|
| August 3, 2022 |
2Q 2022 Investor Update August 1, 2022 PROPRIETARY AND CONFIDENTIAL 22Q 2022 Investor Update Introduction Robert G. |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 01, 2022 EMERGENT BIOSOLUTIONS INC. (Exact name of registrant as specified in its charter) Delaware 001-33137 14-1902018 (State or other jurisdiction (Commission File Number) |
|
| August 3, 2022 |
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2022 •Reports strong core products segment performance offset by impact of continuing post-COVID transition and re-baselining of CDMO services segment •Resumes financial guidance; provides update to full year 2022 outlook GAITHERSBURG, Md. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS |
|
| August 2, 2022 |
Modification No. 29, effective June 16, 2022, to the CDC BioThrax Procurement Contract Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. |
